Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454909 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 873
- Enrollment target
NCT00454909: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00454909 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 873 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (556% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00454909, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 873 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in adolescents/adults 11-25 years of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. The protocol posting has been updated following a protocol amendment.
Primary Outcome
The cut-off value for the hSBA titers was greater than or equal to (≥) 1:8.
Interventions
- BIOLOGICAL Menactra®
- BIOLOGICAL Meningococcal vaccine 134612
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 873 participants |
| Start Date | 2007-04-23 |
| Est. Completion | 2008-04-11 |
| Phase | Phase 2 |
What the finished NCT00454909 record still lists
NCT00454909 is an interventional study that assigns participants to a tested intervention. The registered 873 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (556% higher).
The record links to 0 conditions, and to 2 interventions - of which Menactra® is the first listed.
NCT00454909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00454909 about?
NCT00454909 is a clinical study titled "Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.". The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in adolescents/adults 11-25 years of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. ...
What is the current status of trial NCT00454909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 873 participants. The study started on 2007-04-23. Estimated completion is 2008-04-11.
What interventions are being tested in trial NCT00454909?
The interventions under investigation include: Menactra® (BIOLOGICAL), Meningococcal vaccine 134612 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00454909?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00454909's enrollment target sits among peer trials
873 33rd of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06627647 · 878 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI